Topical testosterone therapy for middle-aged and older men with hypogonadism and either pre-existing or at a high-risk of cardiovascular disease, does increase the risk of adverse cardiac events ...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
The FDA on Thursday approved marketing of a generic version of testosterone gel 1.62% as replacement therapy for men with hypogonadism, according to a press release from Lupin. Testosterone gel 1.62% ...
DUBLIN, Oct. 15, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB-rated generic version of Androgel ® Topical Gel, 1.62% (20.25mg testosterone/1.25g ...
CHICAGO — The Food and Drug Administration has approved a new pocket-sized packet option for a testosterone-replacement therapy made by AbbVie, the drug maker said Friday. AbbVie announced the ...
ABBOTT PARK, Ill., April 29, 2011 /PRNewswire/ -- Abbott (NYSE:ABT - News) announced today that the U.S. Food and Drug Administration (FDA) has approved AndroGel® (testosterone gel) 1.62%, a clear, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback